Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.
Funding Rounds (2) - $12.6MUpdate
|Nov 19, 2015||PRNewswire All - Covered Call Alerts For Mobileye NV, Anavex Life Sciences Corp, SolarEdge Technologies, Microsoft and Consol Energy Released By InvestorsObserver|
|Oct 28, 2015||PRNewswire All - OTC Markets Group Congratulates Anavex Life Sciences on NASDAQ Listing|
|Mar 19, 2014||BioSpace - Anavex Life Sciences Corp Successfully Closes 10|
|Jul 8, 2013||firstwordpharma.com - Anavex raises 2600000 in private_equity round|
51 West 52nd Street
New York, NY NY 10019